Lantern Pharma Inc.
NASDAQ:LTRN

Watchlist Manager
Lantern Pharma Inc. Logo
Lantern Pharma Inc.
NASDAQ:LTRN
Watchlist
Price: 3.08 USD 4.41% Market Closed
Market Cap: 33.2m USD
Have any thoughts about
Lantern Pharma Inc.?
Write Note

Intrinsic Value

LTRN's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

The intrinsic value of one LTRN stock under the Base Case scenario is 3.83 USD. Compared to the current market price of 3.08 USD, Lantern Pharma Inc. is Undervalued by 20%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

LTRN Intrinsic Value
3.83 USD
Undervaluation 20%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Lantern Pharma Inc.

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for LTRN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about LTRN?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Lantern Pharma Inc.

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Lantern Pharma Inc.

Provide an overview of the primary business activities
of Lantern Pharma Inc..

What unique competitive advantages
does Lantern Pharma Inc. hold over its rivals?

What risks and challenges
does Lantern Pharma Inc. face in the near future?

Has there been any significant insider trading activity
in Lantern Pharma Inc. recently?

Summarize the latest earnings call
of Lantern Pharma Inc..

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Lantern Pharma Inc..

Provide P/S
for Lantern Pharma Inc..

Provide P/E
for Lantern Pharma Inc..

Provide P/OCF
for Lantern Pharma Inc..

Provide P/FCFE
for Lantern Pharma Inc..

Provide P/B
for Lantern Pharma Inc..

Provide EV/S
for Lantern Pharma Inc..

Provide EV/GP
for Lantern Pharma Inc..

Provide EV/EBITDA
for Lantern Pharma Inc..

Provide EV/EBIT
for Lantern Pharma Inc..

Provide EV/OCF
for Lantern Pharma Inc..

Provide EV/FCFF
for Lantern Pharma Inc..

Provide EV/IC
for Lantern Pharma Inc..

Show me price targets
for Lantern Pharma Inc. made by professional analysts.

What are the Revenue projections
for Lantern Pharma Inc.?

How accurate were the past Revenue estimates
for Lantern Pharma Inc.?

What are the Net Income projections
for Lantern Pharma Inc.?

How accurate were the past Net Income estimates
for Lantern Pharma Inc.?

What are the EPS projections
for Lantern Pharma Inc.?

How accurate were the past EPS estimates
for Lantern Pharma Inc.?

What are the EBIT projections
for Lantern Pharma Inc.?

How accurate were the past EBIT estimates
for Lantern Pharma Inc.?

Compare the revenue forecasts
for Lantern Pharma Inc. with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Lantern Pharma Inc. and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Lantern Pharma Inc. against its competitors.

Analyze the profit margins
(gross, operating, and net) of Lantern Pharma Inc. compared to its peers.

Compare the P/E ratios
of Lantern Pharma Inc. against its peers.

Discuss the investment returns and shareholder value creation
comparing Lantern Pharma Inc. with its peers.

Analyze the financial leverage
of Lantern Pharma Inc. compared to its main competitors.

Show all profitability ratios
for Lantern Pharma Inc..

Provide ROE
for Lantern Pharma Inc..

Provide ROA
for Lantern Pharma Inc..

Provide ROIC
for Lantern Pharma Inc..

Provide ROCE
for Lantern Pharma Inc..

Provide Gross Margin
for Lantern Pharma Inc..

Provide Operating Margin
for Lantern Pharma Inc..

Provide Net Margin
for Lantern Pharma Inc..

Provide FCF Margin
for Lantern Pharma Inc..

Show all solvency ratios
for Lantern Pharma Inc..

Provide D/E Ratio
for Lantern Pharma Inc..

Provide D/A Ratio
for Lantern Pharma Inc..

Provide Interest Coverage Ratio
for Lantern Pharma Inc..

Provide Altman Z-Score Ratio
for Lantern Pharma Inc..

Provide Quick Ratio
for Lantern Pharma Inc..

Provide Current Ratio
for Lantern Pharma Inc..

Provide Cash Ratio
for Lantern Pharma Inc..

What is the historical Revenue growth
over the last 5 years for Lantern Pharma Inc.?

What is the historical Net Income growth
over the last 5 years for Lantern Pharma Inc.?

What is the current Free Cash Flow
of Lantern Pharma Inc.?

Discuss the annual earnings per share (EPS)
trend over the past five years for Lantern Pharma Inc..

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Lantern Pharma Inc.

Current Assets 29.9m
Cash & Short-Term Investments 28.1m
Other Current Assets 1.9m
Non-Current Assets 372.3k
PP&E 335.6k
Other Non-Current Assets 36.7k
Current Liabilities 3.6m
Accounts Payable 3.4m
Accrued Liabilities 197.3k
Non-Current Liabilities 94k
Other Non-Current Liabilities 94k
Efficiency

Earnings Waterfall
Lantern Pharma Inc.

Revenue
0 USD
Operating Expenses
-21.2m USD
Operating Income
-21.2m USD
Other Expenses
2.1m USD
Net Income
-19.1m USD

Free Cash Flow Analysis
Lantern Pharma Inc.

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

LTRN Profitability Score
Profitability Due Diligence

Lantern Pharma Inc.'s profitability score is 47/100. The higher the profitability score, the more profitable the company is.

47/100
Profitability
Score

Lantern Pharma Inc.'s profitability score is 47/100. The higher the profitability score, the more profitable the company is.

LTRN Solvency Score
Solvency Due Diligence

Lantern Pharma Inc.'s solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
64/100
Solvency
Score

Lantern Pharma Inc.'s solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

LTRN Price Targets Summary
Lantern Pharma Inc.

Wall Street analysts forecast LTRN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LTRN is 22.44 USD with a low forecast of 18.18 USD and a high forecast of 27.3 USD.

Lowest
Price Target
18.18 USD
490% Upside
Average
Price Target
22.44 USD
629% Upside
Highest
Price Target
27.3 USD
786% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for LTRN?

Click here to dive deeper.

Dividends

Lantern Pharma Inc.
does not pay dividends
Shareholder Yield

Current shareholder yield for LTRN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

LTRN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Lantern Pharma Inc. Logo
Lantern Pharma Inc.

Country

United States of America

Industry

Biotechnology

Market Cap

33.2m USD

Dividend Yield

0%

Description

Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. The company is headquartered in Dallas, Texas and currently employs 14 full-time employees. The company went IPO on 2020-06-11. The firm is focused on leveraging artificial intelligence (AI), machine learning and genomic data to streamline the drug development process and to identify the patients, which benefits from its targeted oncology therapies. The Company’s therapies portfolio consists of small molecule drug candidates and new compounds, which it is developing with the assistance of its AI platform and its biomarker driven approach. The Company’s AI platform, RADR uses big data analytics, including combining molecular data, drug efficacy data, data from historical studies, data from scientific literature, phenotypic data from trials and publications, and mechanistic pathway data, and machine learning. The Company’s data-driven, gnomically targeted and biomarker-driven approach allows it to pursue a transformational drug development strategy, which identifies, rescues or develops, and advances potential small molecule drug candidates.

Contact

TEXAS
Dallas
1920 Mckinney Avenue, 7th Floor
+19722771136.0
www.lanternpharma.com

IPO

2020-06-11

Employees

14

Officers

President, CEO & Director
Mr. Panna Sharma PH.D.
CFO & Secretary
Mr. David R. Margrave
Chief Scientific Officer & Scientific Consultant
Dr. Kishor Gopaldas Bhatia Ph.D.
Investor Relations Associate, Finance & Administrative Coordinator
Nicole Leber
Co-Founder & Advisor
Dr. Peter L. Nara D.V.M., M.S., Ph.D.
Head of Clinical Operations
Mr. Ernest Kitt B.S., M.S
Show More
Chief Medical Officer of Starlight Therapeutics
Dr. Marc C. Chamberlain M.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one LTRN stock?

The intrinsic value of one LTRN stock under the Base Case scenario is 3.83 USD.

Is LTRN stock undervalued or overvalued?

Compared to the current market price of 3.08 USD, Lantern Pharma Inc. is Undervalued by 20%.

Back to Top